Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases

A method for the treatment the prophylaxis and/or treatment of alopecia areata comprising the steps of:

• a) measuring the SALT score of an individual by performing a scalp hair loss analysis by assessing the hair loss on the left side, right side, top and back of the patient, wherein the left side and the right side each account for 18% of the overall head surface, the top accounts for 40% of the overall head surface and the back accounts for 24% of the overall head surface,
• b) assessing the type of hair remaining on each area (pigmented/non-pigmented/indeterminant),
• c) calculating a SALT score by the formula:
• d) SALT score=(% left side)*0.18+(% right side)*0.18+(% top side)*0.40+(% back side)*0.24, and
• e) determining a daily dose of the compound according to Formula I, or a pharmaceutically acceptable salt thereof comprised between 25 mg and 400 mg for administration to said individual.

A method for the treatment the prophylaxis and/or treatment of vitiligo comprising the steps of:

• a) measuring the depigmentation of the hands, upper extremities (excluding hands), trunk, lower extremities (excluding the feet), and feet of an individual using the hand as a unit (palm plus the volar surface of all the digits),
• b) calculating a VASI score by the formula:
• VASI=Σall body site[Hand Unit]×[Residual Depigmentation] a.
• c) determining a daily dose of the compound according to Formula I, or a pharmaceutically acceptable salt thereof comprised between 25 mg and 400 mg for administration to said individual.

A method of treating lupus nephritis in an individual afflicted with lupus nephritis, comprising the steps of:

• a) assaying a blood sample,
• b) measuring levels of at least one lupus nephritis-associated biomarker,
• c) administering a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof to the individual,
• d) measuring the post-treatment level of said lupus nephritis-associated biomarker and comparing with pre-treatment levels, and
• e) adjusting the dosage of the compound, or a pharmaceutically acceptable salt thereof to be administered to the individual, wherein said dosage is increased when a decrease of less than 2% after 12 weeks in levels of said lupus nephritis-associated biomarker is detected.

A method of treating sarcoïdosis in an individual afflicted with sarcoïdosis, comprising the steps of:

• a) assaying a blood sample,
• b) measuring levels of at least one sarcoïdosis and/or a sarcoïdosis-related condition-associated biomarker,
• c) administering a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof to the individual,
• d) measuring the post-treatment level of said sarcoïdosis and/or a sarcoïdosis-related condition-associated biomarker and comparing with pre-treatment levels, and
• e) adjusting the dosage of compound, or a pharmaceutically acceptable salt thereof to be administered to the individual, wherein said dosage is increased when a decrease of less than 2% after 12 weeks in levels of said sarcoïdosis and/or a sarcoïdosis-related condition-associated biomarker is detected.

A method for the treatment the prophylaxis and/or treatment of giant cell arteritis comprising the steps of:

• a) measuring the ESR of an individual,
• b) measuring the CRP level of an individual,
• c) comparing said ESR and/or CRP level with normal values,
• d) determining a daily dose of the compound according to Formula I, or a pharmaceutically acceptable salt thereof comprised between 25 mg and 400 mg for administration to said individual.